Population pharmacokinetics of single-dose amikacin in critically ill patients with suspected ventilator-associated pneumonia

European Journal of Clinical Pharmacology

Volumn 71, Issue 1, 2015, Pages 75-83

  Burdet, C ^a,b,c   Pajot, O ^d   Couffignal, C ^a,b,c   Armand Lefevre L ^a,b,c   Foucrier, A ^c   Laouenan C ^a,b,c   Wolff, M ^a,b,c   Massias, L ^c   Mentre F ^a,b,c  

^a UNIVERSITÉ PARIS DIDEROT   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c BICHAT HOSPITAL   (France)

^d CENTRE HOSPITALIER VICTOR DUPOUY   (France)

Author keywords

Amikacin; Intensive care unit; Population pharmacokinetics; Ventilator associated pneumonia

Indexed keywords

AMIKACIN; IMIPENEM; ANTIINFECTIVE AGENT;

ADULT; AGED; ARTICLE; BODY WEIGHT; CRITICALLY ILL PATIENT; DRUG CLEARANCE; DRUG INFUSION; FEMALE; GRAM NEGATIVE BACTERIUM; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK; TREATMENT FAILURE; VENTILATOR ASSOCIATED PNEUMONIA; VOLUME OF DISTRIBUTION; BIOLOGICAL MODEL; CLINICAL TRIAL; CRITICAL ILLNESS; DRUG EFFECTS; GRAM-NEGATIVE BACTERIAL INFECTIONS; GROWTH, DEVELOPMENT AND AGING; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; PNEUMONIA, VENTILATOR-ASSOCIATED; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AMIKACIN; ANTI-BACTERIAL AGENTS; CRITICAL ILLNESS; FEMALE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MODELS, BIOLOGICAL; PNEUMONIA, VENTILATOR-ASSOCIATED;

EID: 84922002877     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-014-1766-y     Document Type: Article

References (41)

1. Bouadma L, Wolff M, Lucet JC (2012) Ventilator-associated pneumonia and its prevention. Curr Opin Infect Dis 25(4):395-404
2. Zahar JR, Timsit JF, Garrouste-Orgeas M, Francais A, Vesin A, Descorps-Declere A, Dubois Y, Souweine B, Haouache H, Goldgran-Toledano D, Allaouchiche B, Azoulay E, Adrie C (2011) Outcomes in severe sepsis and patients with septic shock: pathogen species and infection sites are not associated with mortality. Crit Care Med 39(8):1886-1895
3. Zahar JR, Timsit JF, Garrouste-Orgeas M, Francais A, Vesin A, Descorps-Declere A, Dubois Y, Souweine B, Haouache H, Goldgran-Toledano D, Allaouchiche B, Azoulay E, Adrie C (2005) Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171(4):388-416
4. Barza M, Ioannidis JP, Cappelleri JC, Lau J (1996) Single or multiple daily doses of aminoglycosides: a meta-analysis. BMJ 312(7027):338-345
5. Moore RD, Lietman PS, Smith CR (1987) Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 155(1):93-99
6. Kashuba AD, Nafziger AN, Drusano GL, Bertino JS Jr (1999) Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob Agents Chemother 43(3):623-629
7. Zelenitsky SA, Harding GK, Sun S, Ubhi K, Ariano RE (2003) Treatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis. J Antimicrob Chemother 52(4):668-674
8. Delattre IK, Musuamba FT, Nyberg J, Taccone FS, Laterre PF, Verbeeck RK, Jacobs F, Wallemacq PE (2010) Population pharmacokinetic modeling and optimal sampling strategy for Bayesian estimation of amikacin exposure in critically ill septic patients. Ther Drug Monit 32(6):749-756
9. Bacopoulou F, Markantonis SL, Pavlou E, Adamidou M (2003) A study of once-daily amikacin with low peak target concentrations in intensive care unit patients: pharmacokinetics and associated outcomes. J Crit Care 18(2):107-113
10. Romano S, Fdez DM, de Gatta M, Calvo V, Mendez E, Dominguez-Gil A, Lanao JM (1998) Influence of clinical diagnosis in the population pharmacokinetics of amikacin in intensive care unit patients. Clin Drug Investig 15(5):435-444
11. Lugo G, Castaneda-Hernandez G (1997) Relationship between hemodynamic and vital support measures and pharmacokinetic variability of amikacin in critically ill patients with sepsis. Crit Care Med 25(5):806-811
12. EUCAST Breakpoint tables for interpretation of MICs and zone diameters. Consulted on 03/02/2013, available at : http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST-files/Breakpoint-tables/Breakpoint-table-v-3.1.pdf
13. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, Reinhart CK, Suter PM, Thijs LG (1996) The SOFA (sepsis-related organ failure assessment) score to describe organ dysfunction/failure. On behalf of the working group on sepsis-related problems of the European society of intensive care medicine. Intensive Care Med 22(7):707-710
14. Le Gall JR, Lemeshow S, Saulnier F (1993) A new simplified acute physiology score (SAPS II) based on a European/North American multicenter study. JAMA 270(24):2957-2963
15. White LO, Holt HA, Reeves DS, MacGowan AP (1997) Evaluation of innofluor fluorescence polarization immunoassay kits for the determination of serum concentrations of gentamicin, tobramycin, amikacin and vancomycin. J Antimicrob Chemother 39(3):355-361
16. Samson A, Lavielle M, Mentré F (2006) Extension of the SAEM algorithm to left-censored data in non-linear mixed-effects model: application to HIV dynamics model. Comput Stat Data Anal 51(3):1562-1574
17. Taccone FS, Laterre PF, Spapen H, Dugernier T, Delattre I, Layeux B, De Backer D, Wittebole X, Wallemacq P, Vincent JL, Jacobs F (2010) Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock. Crit Care 14(2):R53
18. Lavielle M, Mentré F (2007) Estimation of population pharmacokinetic parameters of saquinavir in HIV patients with the MONOLIX software. J Pharmacokinet Pharmacodyn 34(2):229-249
19. Gomez CM, Cordingly JJ, Palazzo MG (1999) Altered pharmacokinetics of ceftazidime in critically ill patients. Antimicrob Agents Chemother 43(7):1798-1802
20. Pickering JW, Frampton CM, Walker RJ, Shaw GM, Endre ZH (2012) Four h creatinine clearance is better than plasma creatinine for monitoring renal function in critically ill patients. Crit Care 16(3):R107
21. Galvez R, Luengo C, Cornejo R, Kosche J, Romero C, Tobar E, Illanes V, Llanos O, Castro J (2011) Higher than recommended amikacin loading doses achieve pharmacokinetic targets without associated toxicity. Int J Antimicrob Agents 38(2):146-151
22. Mahmoudi L, Mohammadpour AH, Ahmadi A, Niknam R, Mojtahedzadeh M (2013) Influence of sepsis on higher daily dose of amikacin pharmacokinetics in critically ill patients. Eur Rev Med Pharmacol Sci 17(3):285-291
23. Bertino JS Jr, Booker LA, Franck PA, Jenkins PL, Franck KR, Nafziger AN (1993) Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring. J Infect Dis 167(1):173-179
24. Drusano GL, Ambrose PG, Bhavnani SM, Bertino JS, Nafziger AN, Louie A (2007) Back to the future: using aminoglycosides again and how to dose them optimally. Clin Infect Dis 45(6):753-760
25. Snavely S, Hodges G (1984) The neurotoxicity of antibacterial agents. Ann Intern Med 101(1):92-104
26. Roberts JA, Lipman J (2009) Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 37(3):840-851, quiz 859
27. Pea F, Viale P, Furlanut M (2005) Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet 44(10):1009-1034
28. Lode H, Grunert K, Koeppe P, Langmaack H (1976) Pharmacokinetic and clinical studies with amikacin, a new aminoglycoside antibiotic. J Infect Dis 134(SUPPL):S316-S322
29. Tormo C, Abad FJ, Ronchera-Oms CL, Parra V, Jimenez NV (1995) Critically-ill patients receiving total parenteral nutrition show altered amikacin pharmacokinetics. Clin Nutr 14(4):254-259
30. Marik PE (1993) Aminoglycoside volume of distribution and illness severity in critically ill septic patients. Anaesth Intensive Care 21(2):172-173
31. Bressolle F, Gouby A, Martinez JM, Joubert P, Saissi G, Guillaud R, Gomeni R (1996) Population pharmacokinetics of amikacin in critically ill patients. Antimicrob Agents Chemother 40(7):1682-1689
32. Marik PE, Havlik I, Monteagudo FS, Lipman J (1991) The pharmacokinetic of amikacin in critically ill adult and paediatric patients: comparison of once- versus twice-daily dosing regimens. J Antimicrob Chemother 27(Suppl C):81-89
33. Fernandez M, de Gatta MD, Victoria Calvo M, Ardanuy R, Dominguez-Gil A, Lanao JM, Moreno SR (2009) Evaluation of population pharmacokinetic models for amikacin dosage individualization in critically ill patients. J Pharm Pharmacol 61(6):759-766
34. McLeay SC, Morrish GA, Kirkpatrick CM, Green B (2012) The relationship between drug clearance and body size: systematic review and meta-analysis of the literature published from 2000 to 2007. Clin Pharmacokinet 51(5):319-330
35. Edwards CQ, Smith CR, Baughman KL, Rogers JF, Lietman PS (1976) Concentrations of gentamicin and amikacin in human kidneys. Antimicrob Agents Chemother 9(6):925-927
36. French MA, Cerra FB, Plaut ME, Schentag JJ (1981) Amikacin and gentamicin accumulation pharmacokinetics and nephrotoxicity in critically ill patients. Antimicrob Agents Chemother 19(1):147-152
37. Joubert P, Bressolle F, Gouby A, Doucot PY, Saissi G, Gomeni R (1999) A population approach to the forecasting of amikacin plasma and urinary levels using a prescribed dosage regimen. Eur J Drug Metab Pharmacokinet 24(1):39-46
38. Savey A, Machut A (2012) Surveillance des infections nosocomiales en réanimation adulte. Réseau REA-Raisin, France, Résultats 2011. Available at http://www.invs.sante.fr/%20fr/Publications-et-outils/Rapports-et-syntheses/Maladies-infectieuses/2013/Surveillance-des-infections-nosocomiales-en-reanimation-adulte. In: ed
39. Frei CR, Wiederhold NP, Burgess DS (2008) Antimicrobial breakpoints for gram-negative aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation. J Antimicrob Chemother 61(3):621-628
40. Carlier M, Noe M, De Waele JJ, Stove V, Verstraete AG, Lipman J, Roberts JA (2013) Population pharmacokinetics and dosing simulations of amoxicillin/clavulanic acid in critically ill patients. J Antimicrob Chemother 68(11):2600-2608
41. de Montmollin E, Bouadma L, Gault N, Mourvillier B, Mariotte E, Chemam S et al. (2014) Predictors of insufficient amikacin peak concentration in critically ill patients receiving a 25 mg/kg total body weight regimen. Intensive Care Med